Structural manipulation of eicosanoid receptors and cellular signaling

TheScientificWorldJournal

Volumn 7, Issue , 2007, Pages 1285-1306

  Brink, Charles ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

GPCRs; Leukotriene receptors; Leukotrienes; Prostaglandins; Prostanoid receptors; Receptor signaling; Receptor structure

Indexed keywords

1 [2 METHOXY 4 [(PHENYLSULFONYLAMINO)CARBONYL]BENZYL] 1H INDAZOLE 6 CARBAMIC ACID CYCLOPENTYL ESTER; 7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; 9BETA CHLORO 15 CYCLOHEXYL 9 DEOXY 16,17,18,19,20 PENTANOR 3 OXAPROSTAGLANDIN F2 ALPHA; AMINO ACID; BUTAPROST; EICOSANOID RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MISOPROSTOL; MONTELUKAST; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RECEPTOR; RHODOPSIN; SULPROSTONE; UNCLASSIFIED DRUG; VERLUKAST;

AMINO ACID SUBSTITUTION; ASTHMA; CARBOXY TERMINAL SEQUENCE; CYTOPLASM; DNA SEQUENCE; DRUG POTENCY; GENETICS; HUMAN; HYDROLYSIS; LIGAND BINDING; MEMBRANE BINDING; MUTAGENESIS; NONHUMAN; PHYLOGENY; POINT MUTATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; CYTOPLASM; GTP-BINDING PROTEINS; HUMANS; LIGANDS; MUTAGENESIS; PROTEIN BINDING; RECEPTORS, EICOSANOID; SIGNAL TRANSDUCTION;

EID: 34548787931     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2007.163     Document Type: Review

References (123)

1. Coleman, R.A., Smith, W.L., and Narumiya, S. (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46, 205-229.
2. Bhattacharya, M., Peri, K., Ribeiro-da-Silva, A., Almazan, G., Shichi, H., Hou, X., Varma, D.R., and Chemtob, S. (1999) Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J. Biol. Chem. 274, 15719-15724.
3. Bhattacharya, M., Peri, K.G., Almazan, G., Ribeiro-da-Silva, A., Shichi, H., Durocher, Y., Abramovitz, M., Hou, X., Varma, D.R., and Chemtob, S. (1998) Nuclear localization of prostaglandin E2 receptors. Proc. Natl. Acad. Sci. U. S. A. 95, 15792-15797.
4. Kanai, N., Lu, R., Satriano, J.A., Bao, Y., Wolkoff, A.W., and Schuster, V.L. (1995) Identification and characterization of a prostaglandin transporter. Science 268, 866-869.
5. Itoh, S., Lu, R., Bao, Y., Morrow, J.D., Roberts, L.J., and Schuster, V.L. (1996) Structural determinants of substrates for the prostaglandin transporter PGT. Mol. Pharmacol. 50, 738-742.
6. Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M., and Evans, R.M. (1995) 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83, 803-812.
7. Nakano, J., Anggard, E., and Samuelsson, B. (1969) 15-Hydroxy-prostanoate dehydrogenase. Prostaglandins as substrates and inhibitors. Eur. J. Biochem. 11, 386-389.
8. Smith, W.L. (1992) Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol. 263, F181-191.
9. Brink, C., Dahlen, S.E., Drazen, J., Evans, J.F., Hay, D.W., Rovati, G.E., Serhan, C.N., Shimizu, T., and Yokomizo, T. (2004) International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol. Rev. 56, 149-157.
10. Devchand, P.R., Keller, H., Peters, J.M., Vazquez, M., Gonzalez, F.J., and Wahli, W. (1996) The PPARalphaleukotriene B4 pathway to inflammation control. Nature 384, 39-43.
11. Keppler, D., Muller, M., Klunemann, C., Guhlmann, A., Krauss, K., Muller, J., Berger, U., Leier, I., and Mayatepek, E. (1992) Transport and in vivo elimination of cysteinyl leukotrienes. Adv. Enzyme Regul. 32, 107-116.
12. Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A., and Serhan, C.N. (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237, 1171-1176.
13. Yokomizo, T., Izumi, T., Takahashi, T., Kasama, T., Kobayashi, Y., Sato, F., Taketani, Y., and Shimizu, T. (1993) Enzymatic inactivation of leukotriene B4 by a novel enzyme found in the porcine kidney. Purification and properties of leukotriene B4 12-hydroxydehydrogenase. J. Biol. Chem. 268, 18128-18135.
14. Hori, T., Yokomizo, T., Ago, H., Sugahara, M., Ueno, G., Yamamoto, M., Kumasaka, T., Shimizu, T., and Miyano, M. (2004) Structural basis of leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop. J. Biol. Chem. 279, 22615-22623.
15. Ungrin, M.D., Carriere, M.C., Denis, D., Lamontagne, S., Sawyer, N., Stocco, R., Tremblay, N., Metters, K.M., and Abramovitz, M. (2001) Key structural features of prostaglandin E(2) and prostanoid analogs involved in binding and activation of the human EP(1) prostanoid receptor. Mol. Pharmacol. 59, 1446-1456.
16. Abramovitz, M., Adam, M., Boie, Y., Carriere, M., Denis, D., Godbout, C., Lamontagne, S., Rochette, C., Sawyer, N., Tremblay, N.M., Belley, M., Gallant, M., Dufresne, C., Gareau, Y., Ruel, R., Juteau, H., Labelle, M., Ouimet, N., and Metters, K.M. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483, 285-293.
17. Stillman, B.A., Audoly, L., and Breyer, R.M. (1998) A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding. Eur. J. Pharmacol. 357, 73-82.
18. Audoly, L. and Breyer, R.M. (1997) The second extracellular loop of the prostaglandin EP3 receptor is an essential determinant of ligand selectivity. J. Biol. Chem. 272, 13475-13478.
19. Funk, C.D., Furci, L., FitzGerald, G.A., Grygorczyk, R., Rochette, C., Bayne, M.A., Abramovitz, M., Adam, M., and Metters, K.M. (1993) Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J. Biol. Chem. 268, 26767-26772.
20. Huang, C. and Tai, H.H. (1996) Ser-268 plays an important role in ligand binding of prostaglandin E2 receptor EP3alpha subtype. Arch. Biochem. Biophys. 327, 161-166.
21. Yamamoto, Y., Kamiya, K., and Terao, S. (1993) Modeling of human thromboxane A2 receptor and analysis of the receptor-ligand interaction. J. Med. Chem. 36, 820-825.
22. Chang, C.S., Negishi, M., Nishigaki, N., and Ichikawa, A. (1997) Characterization of functional interaction of carboxylic acid group of agonists and arginine of the seventh transmembrane domains of four prostaglandin E receptor subtypes. Prostaglandins 54, 437-446.
23. Schaaf, T.K. and Hess, H.J. (1979) Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues. J. Med. Chem. 22, 1340-1346.
24. Lawson, J.A., Rokach, J., and FitzGerald, G.A. (1999) Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem. 274, 24441-24444.
25. Sametz, W., Hennerbichler, S., Glaser, S., Wintersteiger, R., and Juan, H. (2000) Characterization of prostanoid receptors mediating actions of the isoprostanes, 8-iso-PGE(2) and 8-iso-PGF(2alpha), in some isolated smooth muscle preparations. Br. J. Pharmacol. 130, 1903-1910.
26. Wilson, R.J., Rhodes, S.A., Wood, R.L., Shield, V.J., Noel, L.S., Gray, D.W., and Giles, H. (2004) Functional pharmacology of human prostanoid EP2 and EP4 receptors. Eur. J. Pharmacol. 501, 49-58.
27. Giles, H., Leff, P., Bolofo, M.L., Kelly, M.G., and Robertson, A.D. (1989) The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br. J. Pharmacol. 96, 291-300.
28. Lydford, S.J., McKechnie, K.C., and Dougall, I.G. (1996) Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br. J. Pharmacol. 117, 13-20.
29. Ohia, S.E. and Jumblatt, J.E. (1990) Prejunctional inhibitory effects of prostanoids on sympathetic neurotransmission in the rabbit iris-ciliary body. J. Pharmacol. Exp. Ther. 255, 11-16.
30. Kiriyama, M., Ushikubi, F., Kobayashi, T., Hirata, M., Sugimoto, Y., and Narumiya, S. (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122, 217-224.
31. Wright, D.H., Metters, K.M., Abramovitz, M., and Ford-Hutchinson, A.W. (1998) Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br. J. Pharmacol. 123, 1317-1324.
32. Sharif, N.A., Crider, J.Y., Xu, S.X., and Williams, G.W. (2000) Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J. Pharmacol. Exp. Ther. 293, 321-328.
33. Norel, X., de Montpreville, V., and Brink, C. (2004) Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat. 74, 101-112.
34. Monneret, G., Cossette, C., Gravel, S., Rokach, J., and Powell, W.S. (2003) 15R-methyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils. J. Pharmacol. Exp. Ther. 304, 349-355.
35. Schuster, V.L., Itoh, S., Andrews, S.W., Burk, R.M., Chen, J., Kedzie, K.M., Gil, D.W., and Woodward, D.F. (2000) Synthetic modification of prostaglandin f(2alpha) indicates different structural determinants for binding to the prostaglandin F receptor versus the prostaglandin transporter. Mol. Pharmacol. 58, 1511-1516.
36. Drazen, J. (1998) Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am. J. Respir. Crit. Care Med. 157, S233-237; discussion S247-238.
37. Augstein, J., Farmer, J.B., Lee, T.B., Sheard, P., and Tattersall, M.L. (1973) Selective inhibitor of slow reacting substance of anaphylaxis. Nat. New Biol. 245, 215-217.
38. Jones, T.R., Labelle, M., Belley, M., Champion, E., Charette, L., Evans, J., Ford-Hutchinson, A.W., Gauthier, J.Y., Lord, A., Masson, P., et al. (1995) Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 73, 191-201.
39. Jones, T.R., Zamboni, R., Belley, M., Champion, E., Charette, L., Ford-Hutchinson, A.W., Gauthier, J.Y., Leger, S., Lord, A., Masson, P., et al. (1991) Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571. Can. J. Physiol. Pharmacol. 69, 1847-1854.
40. Jones, T.R., Zamboni, R., Belley, M., Champion, E., Charette, L., Ford-Hutchinson, A.W., Frenette, R., Gauthier, J.Y., Leger, S., Masson, P., et al. (1989) Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 67, 17-28.
41. Guay, D., Gauthier, J.Y., Dufresne, C., Jones, T.R., McAuliffe, M., McFarlane, C., Metters, K.M., Prasit, P., Rochette, C., Roy, P., Sawyer, N., and Zamboni, R. (1998) A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair. Bioorg. Med. Chem. Lett. 8, 453-458.
42. Young, R.N. (1989) Structural analysis of sulfido-peptide leukotrienes: application to the design of potent and specific antagonists of leukotriene D4. Adv. Prostaglandin Thromboxane Leukot. Res. 19, 643-646.
43. Young, R.N. (1988) The development of new anti-leukotriene drugs: L-648,051 and L-649,923, specific leukotriene D4 antagonists. Drugs Future 13, 745-759.
44. Yee, Y.K., Bernstein, P.R., Adams, E.J., Brown, F.J., Cronk, L.A., Hebbel, K.C., Vacek, E.P., Krell, R.D., and Snyder, D.W. (1990) A novel series of selective leukotriene antagonists: exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles. J. Med. Chem. 33, 2437-2451.
45. Zwaagstra, M.E., Timmerman, H., van de Stolpe, A.C., de Kanter, F.J., Tamura, M., Wada, Y., and Zhang, M.Q. (1998) Synthesis and structure-activity relationships of carboxyflavones as structurally rigid CysLT1 (LTD4) receptor antagonists. J. Med. Chem. 41, 1428-1438.
46. Zwaagstra, M.E., Schoenmakers, S.H., Nederkoorn, P.H., Gelens, E., Timmerman, H., and Zhang, M.Q. (1998) Development of a three-dimensional CysLT1 (LTD4) antagonist model with an incorporated amino acid residue from the receptor. J. Med. Chem. 41, 1439-1445.
47. Bernstein, P.R. (1998) Chemistry and structure-activity relationships of leukotriene receptor antagonists. Am. J. Respir. Crit. Care Med. 157, S220-226.
48. Zhang, M.Q., Zwaagstra, M.E., Nederkoorn, P.H.J., and Timmerman, H. (1997) The role of arginine in the binding of LTD4 antagonists to CysLT1 receptors of guinea pig lung. Bioorg. Med. Chem. Lett. 7, 1331-1336.
49. Pierce, K.L., Gil, D.W., Woodward, D.F., and Regan, J.W. (1995) Cloning of human prostanoid receptors. Trends Pharmacol. Sci. 16, 253-256.
50. Fujino, H. and Regan, J.W. (2003) Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? Trends Pharmacol. Sci. 24, 335-340.
51. Pierce, K.L. and Regan, J.W. (1998) Prostanoid receptor heterogeneity through alternative mRNA splicing. Life Sci. 62, 1479-1483.
52. Okuda-Ashitaka, E., Sakamoto, K., Ezashi, T., Miwa, K., Ito, S., and Hayaishi, O. (1996) Suppression of prostaglandin E receptor signaling by the variant form of EP1 subtype. J. Biol. Chem. 271, 31255-31261.
53. Hibert, M.F., Trumpp-Kallmeyer, S., Bruinvels, A., and Hoflack, J. (1991) Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol. Pharmacol. 40, 8-15.
54. Negishi, M., Irie, A., Sugimoto, Y., Namba, T., and Ichikawa, A. (1995) Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of alpha-carboxylic acid of agonist and arginine residue of seventh transmembrane domain. J. Biol. Chem. 270, 16122-16127.
55. Funk, C.D., Furci, L., Moran, N., and Fitzgerald, G.A. (1993) Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. Mol. Pharmacol. 44, 934-939.
56. Dorn, G.W., 2nd, Davis, M.G., and D'Angelo, D.D. (1997) Structural determinants for agonist binding affinity to thromboxane/prostaglandin endoperoxide (TP) receptors. Analysis of chimeric rat/human TP receptors. J. Biol. Chem. 272, 12399-12405.
57. Kedzie, K.M., Donello, J.E., Krauss, H.A., Regan, J.W., and Gil, D.W. (1998) A single amino-acid substitution in the EP2 prostaglandin receptor confers responsiveness to prostacyclin analogs. Mol. Pharmacol. 54, 584-590.
58. Kobayashi, T., Kiriyama, M., Hirata, T., Hirata, M., Ushikubi, F., and Narumiya, S. (1997) Identification of domains conferring ligand binding specificity to the prostanoid receptor. Studies on chimeric prostacyclin/ prostaglandin D receptors. J. Biol. Chem. 272, 15154-15160.
59. Kobayashi, T., Ushikubi, F., and Narumiya, S. (2000) Amino acid residues conferring ligand binding properties of prostaglandin I and prostaglandin D receptors. Identification by site-directed mutagenesis. J. Biol. Chem. 275, 24294-24303.
60. Chiang, N., Fierro, I.M., Gronert, K., and Serhan, C.N. (2000) Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J. Exp. Med. 191, 1197-1208.
61. Gearing, K.L., Barnes, A., Barnett, J., Brown, A., Cousens, D., Dowell, S., Green, A., Patel, K., Thomas, P., Volpe, F., and Marshall, F. (2003) Complex chimeras to map ligand binding sites of GPCRs. Protein Eng. 16, 365-372.
62. Sabirsh, A., Bywater, R.P., Bristulf, J., Owman, C., and Haeggstrom, J.Z. (2006) Residues from transmembrane helices 3 and 5 participate in leukotriene B4 binding to BLT1. Biochemistry 45, 5733-5744.
63. Baneres, J.L., Martin, A., Hullot, P., Girard, J.P., Rossi, J.C., and Parello, J. (2003) Structure-based analysis of GPCR function: conformational adaptation of both agonist and receptor upon leukotriene B4 binding to recombinant BLT1. J. Mol. Biol. 329, 801-814.
64. Baneres, J.L. and Parello, J. (2003) Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J. Mol. Biol. 329, 815-829.
65. D'Angelo, D.D., Eubank, J.J., Davis, M.G., and Dorn, G.W., 2nd (1996) Mutagenic analysis of platelet thromboxane receptor cysteines. Roles in ligand binding and receptor-effector coupling. J. Biol. Chem. 271, 6233-6240.
66. So, S.P., Wu, J., Huang, G., Huang, A., Li, D., and Ruan, K.H. (2003) Identification of residues important for ligand binding of thromboxane A2 receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach. J. Biol. Chem. 278, 10922-10927.
67. Olah, M.E., Jacobson, K.A., and Stiles, G.L. (1994) Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors. J. Biol. Chem. 269, 24692-24698.
68. Chiang, N., Kan, W.M., and Tai, H.H. (1996) Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A2 receptor in insect cells. Arch. Biochem. Biophys. 334, 9-17.
69. Ruan, C.H., Wu, J., and Ruan, K.H. (2005) A strategy using NMR peptide structures of thromboxane A2 receptor as templates to construct ligand-recognition pocket of prostacyclin receptor. BMC Biochem. 6, 23.
70. Ruan, K.H., So, S.P., Wu, J., Li, D., Huang, A., and Kung, J. (2001) Solution structure of the second extracellular loop of human thromboxane A2 receptor. Biochemistry 40, 275-280.
71. Ruan, K.H., Wu, J., So, S.P., Jenkins, L.A., and Ruan, C.H. (2004) NMR structure of the thromboxane A2 receptor ligand recognition pocket. Eur. J. Biochem. 271, 3006-3016.
72. Turek, J.W., Halmos, T., Sullivan, N.L., Antonakis, K., and Le Breton, G.C. (2002) Mapping of a ligand-binding site for the human thromboxane A2 receptor protein. J. Biol. Chem. 277, 16791-16797.
73. Huang, C. and Tai, H.H. (1995) Expression and site-directed mutagenesis of mouse prostaglandin E2 receptor EP3 subtype in insect cells. Biochem. J. 307(Pt 2), 493-498.
74. Walsh, M.T., Foley, J.F., and Kinsella, B.T. (1998) Characterization of the role of N-linked glycosylation on the cell signaling and expression of the human thromboxane A2 receptor alpha and beta isoforms. J. Pharmacol. Exp. Ther. 286, 1026-1036.
75. Fraser, C.M. (1989) Site-directed mutagenesis of beta-adrenergic receptors. Identification of conserved cysteine residues that independently affect ligand binding and receptor activation. J. Biol. Chem. 264, 9266-9270.
76. Hirata, T., Kakizuka, A., Ushikubi, F., Fuse, I., Okuma, M., and Narumiya, S. (1994) Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J. Clin. Invest. 94, 1662-1667.
77. Pal-Ghosh, R., Yu, J., Prado, G.N., Taylor, L., Mierke, D.F., and Polgar, P. (2003) Chimeric exchanges within the bradykinin B2 receptor intracellular face with the prostaglandin EP2 receptor as the donor: importance of the second intracellular loop for cAMP synthesis. Arch. Biochem. Biophys. 415, 54-62.
78. Yu, J., Prado, G.N., Schreiber, B., Polgar, P., Polgar, P., and Taylor, L. (2002) Role of prostaglandin E(2) EP receptors and cAMP in the expression of connective tissue growth factor. Arch. Biochem. Biophys. 404, 302-308.
79. Pierce, K.L., Bailey, T.J., Hoyer, P.B., Gil, D.W., Woodward, D.F., and Regan, J.W. (1997) Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. J. Biol. Chem. 272, 883-887.
80. Slipetz, D., Buchanan, S., Mackereth, C., Brewer, N., Pellow, V., Hao, C., Adam, M., Abramovitz, M., and Metters, K.M. (2001) Sequestration and phosphorylation of the prostaglandin E2 EP4 receptor: dependence on the C-terminal tail. Biochem. Pharmacol. 62, 997-1012.
81. Smyth, E.M., Li, W.H., and FitzGerald, G.A. (1998) Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c. J. Biol. Chem. 273, 23258-23266.
82. Hasse, A., Nilius, S.M., Schror, K., and Meyer-Kirchrath, J. (2003) Long-term-desensitization of prostacyclin receptors is independent of the C-terminal tail. Biochem. Pharmacol. 65, 1991-1995.
83. Smyth, E.M., Austin, S.C., Reilly, M.P., and FitzGerald, G.A. (2000) Internalization and sequestration of the human prostacyclin receptor. J. Biol. Chem. 275, 32037-32045.
84. Nagata, K., Hirai, H., Tanaka, K., Ogawa, K., Aso, T., Sugamura, K., Nakamura, M., and Takano, S. (1999) CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 459, 195-199.
85. Hata, A.N., Lybrand, T.P., Marnett, L.J., and Breyer, R.M. (2005) Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol. Pharmacol. 67, 640-647.
86. Hata, A.N., Lybrand, T.P., and Breyer, R.M. (2005) Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2. J. Biol. Chem. 280, 32442-32451.
87. Stitham, J., Stojanovic, A., Ross, L.A., Blount, A.C., Jr., and Hwa, J. (2004) Clusters of transmembrane residues are critical for human prostacyclin receptor activation. Biochemistry 43, 8974-8986.
88. Kristiansen, K. (2004) Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther. 103, 21-80.
89. Okuno, T., Ago, H., Terawaki, K., Miyano, M., Shimizu, T., and Yokomizo, T. (2003) Helix 8 of the leukotriene B4 receptor is required for the conformational change to the low affinity state after G-protein activation. J. Biol. Chem. 278, 41500-41509.
90. Gaudreau, R., Beaulieu, M.E., Chen, Z., Le Gouill, C., Lavigne, P., Stankova, J., and Rola-Pleszczynski, M. (2004) Structural determinants regulating expression of the high affinity leukotriene B4 receptor: involvement of dileucine motifs and alpha-helix VIII. J. Biol. Chem. 279, 10338-10345.
91. Gaudreau, R., Le Gouill, C., Venne, M.H., Stankova, J., and Rola-Pleszczynski, M. (2002) Threonine 308 within a putative casein kinase 2 site of the cytoplasmic tail of leukotriene B(4) receptor (BLT1) is crucial for ligand-induced, G-protein-coupled receptor-specific kinase 6-mediated desensitization. J. Biol. Chem. 277, 31567-31576.
92. Okuno, T., Yokomizo, T., Hori, T., Miyano, M., and Shimizu, T. (2005) Leukotriene B4 receptor and the function of its helix 8. J. Biol. Chem. 280, 32049-32052.
93. Basu, S., Jala, V.R., Mathis, S., Rajagopal, S.T., Del Prete, A., Maturu, P., Trent, J.O., and Haribabu, B. (2007) Critical role for polar residues in coupling leukotriene B4 binding to signal transduction in BLT1. J. Biol. Chem. 282, 10005-10017.
94. Damian, M., Martin, A., Mesnier, D., Pin, J.P., and Baneres, J.L. (2006) Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J. 25, 5693-5702.
95. Hata, A.N. and Breyer, R.M. (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103, 147-166.
96. Parent, J.L., Labrecque, P., Orsini, M.J., and Benovic, J.L. (1999) Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J. Biol. Chem. 274, 8941-8948.
97. Parent, J.L., Labrecque, P., Driss Rochdi, M., and Benovic, J.L. (2001) Role of the differentially spliced carboxyl terminus in thromboxane A2 receptor trafficking: identification of a distinct motif for tonic internalization. J. Biol. Chem. 276, 7079-7085.
98. Khasawneh, F.T., Huang, J.S., Turek, J.W., and Le Breton, G.C. (2006) Differential mapping of the amino acids mediating agonist and antagonist coordination with the human thromboxane A2 receptor protein. J. Biol. Chem. 281, 26951-26965.
99. Nishigaki, N., Negishi, M., and Ichikawa, A. (1996) Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol. Pharmacol. 50, 1031-1037.
100. Irie, A., Sugimoto, Y., Namba, T., Harazono, A., Honda, A., Watabe, A., Negishi, M., Narumiya, S., and Ichikawa, A. (1993) Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur. J. Biochem. 217, 313-318.
101. Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., Ito, S., Ichikawa, A., and Narumiya, S. (1993) Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 365, 166-170.
102. Hasegawa, H., Negishi, M., and Ichikawa, A. (1996) Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity. J. Biol. Chem. 271, 1857-1860.
103. Neuschafer-Rube, F., Hanecke, K., Blaschke, V., Jungermann, K., and Puschel, G.P. (1997) The C-terminal domain of the Gs-coupled EP4 receptor confers agonist-dependent coupling control to Gi but no coupling to Gs in a receptor hybrid with the Gi-coupled EP3 receptor. FEBS Lett. 401, 185-190.
104. Neuschafer-Rube, F., Hanecke, K., and Puschel, G.P. (1997) The C-terminal domain of the human EP4 receptor confers agonist-induced receptor desensitization in a receptor hybrid with the rat EP3beta receptor. FEBS Lett. 415, 119-124.
105. Bastepe, M. and Ashby, B. (1999) Identification of a region of the C-terminal domain involved in short-term desensitization of the prostaglandin EP4 receptor. Br. J. Pharmacol. 126, 365-371.
106. Desai, S., April, H., Nwaneshiudu, C., and Ashby, B. (2000) Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. Mol. Pharmacol. 58, 1279-1286.
107. Miggin, S.M., Lawler, O.A., and Kinsella, B.T. (2002) Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. Eur. J. Biochem. 269, 1714-1725.
108. Miggin, S.M., Lawler, O.A., and Kinsella, B.T. (2003) Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J. Biol. Chem. 278, 6947-6958.
109. Fujino, H., Srinivasan, D., Pierce, K.L., and Regan, J.W. (2000) Differential regulation of prostaglandin F(2alpha) receptor isoforms by protein kinase C. Mol. Pharmacol. 57, 353-358.
110. Srinivasan, D., Fujino, H., and Regan, J.W. (2002) Differential internalization of the prostaglandin f(2alpha) receptor isoforms: role of protein kinase C and clathrin. J. Pharmacol. Exp. Ther. 302, 219-224.
111. Fujino, H., Srinivasan, D., and Regan, J.W. (2002) Cellular conditioning and activation of beta-catenin signaling by the FPB prostanoid receptor. J. Biol. Chem. 277, 48786-48795.
112. Sugimoto, Y., Namba, T., Honda, A., Hayashi, Y., Negishi, M., Ichikawa, A., and Narumiya, S. (1992) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J. Biol. Chem. 267, 6463-6466.
113. Chiang, N., Serhan, C.N., Dahlen, S.E., Drazen, J.M., Hay, D.W., Rovati, G.E., Shimizu, T., Yokomizo, T., and Brink, C. (2006) The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58, 463-487.
114. Schaldach, C.M., Riby, J., and Bjeldanes, L.F. (1999) Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry 38, 7594-7600.
115. Machado, F.S., Johndrow, J.E., Esper, L., Dias, A., Bafica, A., Serhan, C.N., and Aliberti, J. (2006) Antiinflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12, 330-334.
116. Nonaka, Y., Hiramoto, T., and Fujita, N. (2005) Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem. Biophys. Res. Commun. 337, 281-288.
117. Capra, V., Ravasi, S., Accomazzo, M.R., Citro, S., Grimoldi, M., Abbracchio, M.P., and Rovati, G.E. (2005) CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation. J. Cell Sci. 118, 5625-5636.
118. Mamedova, L., Capra, V., Accomazzo, M.R., Gao, Z.G., Ferrario, S., Fumagalli, M., Abbracchio, M.P., Rovati, G.E., and Jacobson, K.A. (2005) CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochem. Pharmacol. 71, 115-125.
119. Ciana, P., Fumagalli, M., Trincavelli, M.L., Verderio, C., Rosa, P., Lecca, D., Ferrario, S., Parravicini, C., Capra, V., Gelosa, P., Guerrini, U., Belcredito, S., Cimino, M., Sironi, L., Tremoli, E., Rovati, G.E., Martini, C., and Abbracchio, M.P. (2006) The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinylleukotrienes receptor. EMBO J. 25, 4615-4627.
120. Back, M., Norel, X., Walch, L., Gascard, J., Mazmanian, G., Dahlen, S., and Brink, C. (2000) Antagonist resistant contractions of the porcine pulmonary artery by cysteinyl-leukotrienes. Eur. J. Pharmacol. 401, 381-388.
121. Walch, L., Norel, X., Back, M., Gascard, J.P., Dahlen, S.E., and Brink, C. (2002) Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br. J. Pharmacol. 137, 1339-1345.
122. Ravasi, S., Capra, V., Mezzetti, M., Nicosia, S., and Rovati, G.E. (2000) A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma. Mol. Pharmacol. 57, 1182-1189.
123. Ravasi, S., Capra, V., Panigalli, T., Rovati, G.E., and Nicosia, S. (2002) Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem. Pharmacol. 63, 1537-1546.